BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23558940)

  • 41. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.
    Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T
    Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
    Banks RE; Tirukonda P; Taylor C; Hornigold N; Astuti D; Cohen D; Maher ER; Stanley AJ; Harnden P; Joyce A; Knowles M; Selby PJ
    Cancer Res; 2006 Feb; 66(4):2000-11. PubMed ID: 16488999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Frequent somatic mutations of the von Hippel-Lindau tumor suppressor gene in primary sporadic human renal clear cell carcinomas].
    Gong K; Zhang Z; Xin D
    Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(3):142-4. PubMed ID: 11798864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
    Singh RB; Amare Kadam PS
    Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Inactivation of the VHL gene in sporadic clear cell renal cancer].
    Mikhaĭlenko DS; Kurynin RB; Popov AM; Kariakin OB; Enikeev ME; Aliaev IuG; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2008; 42(1):71-7. PubMed ID: 18389622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer].
    Mikhaĭlenko DS; Grigor'eva MV; Rusakov IG; Kurynin RV; Popov AM; Peters MV; Matveev VB; Iakovlev ES; Nosov DA; Liubchenko LN; Tiuliandin SA; Strel'nikov VV; Zaletaev DV
    Mol Biol (Mosk); 2012; 46(1):71-81. PubMed ID: 22642103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
    Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
    Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
    Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B
    Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma.
    Tabata M; Sato Y; Kogure Y; McClure MB; Oshikawa-Kumade Y; Saito Y; Shingaki S; Ito Y; Yuasa M; Koya J; Yoshida K; Kohno T; Miyama Y; Morikawa T; Chiba K; Okada A; Ogawa S; Ushiku T; Shiraishi Y; Kume H; Kataoka K
    Cell Rep; 2023 Jul; 42(7):112736. PubMed ID: 37405915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
    Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors.
    Vortmeyer AO; Huang SC; Koch CA; Governale L; Dickerman RD; McKeever PE; Oldfield EH; Zhuang Z
    Cancer Res; 2000 Nov; 60(21):5963-5. PubMed ID: 11085513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
    Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
    Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
    Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
    Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients.
    Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M
    Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular analysis as a tool in the differential diagnosis of VHL disease-related tumors.
    Gijtenbeek J; Jacobs B; Boots-Sprenger S; Bonne A; Lenders J; Küsters B; Wesseling P; Jeuken J
    Diagn Mol Pathol; 2005 Jun; 14(2):115-20. PubMed ID: 15905696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Development of human renal cell carcinoma (RCC)--the responsible genes for the development of hereditary and sporadic human RCCs].
    Shuin T; Kamata M; Ashida S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1719-25. PubMed ID: 12402420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.